Related Experiment Video

Updated: Mar 28, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.2K

Ebola vaccine R&D: Filling the knowledge gaps

Donata Medaglini1, Ali M Harandi2, Tom H M Ottenhoff3

  • 1Laboratorio di Microbiologia Molecolare e Biotecnologia (LA.M.M.B.), Dipartimento di Biotecnologie Mediche, Università di Siena, 53100 Siena, Italy. Sclavo Vaccines Association, 53100 Siena, Italy. donata.medaglini@unisi.it.

Science Translational Medicine
|December 15, 2015
PubMed

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.8K
Remote Laboratory Management: Respiratory Virus Diagnostics14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

33.8K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
33.8K
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
57